U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

The stock's fall snapped a two-day winning streak.

Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...

This was the stock's second consecutive day of gains.

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...